Antoine Jakiche, MD
Gastroenterology · Albuquerque, NMNPI 1609875996
Payments from drug & device makers
Across 579 payments — averaging $1634.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$314K
- Intercept Pharmaceuticals, Inc.$244K
- Novartis$147K
- Ipsen Bioscience Inc.$100K
- Gilead$74K
- Madrigal Pharmaceuticals$37K
- plus $30K from 33 others
Across 1 payment — averaging $934.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$934
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 196 | $314,218 |
| Intercept Pharmaceuticals, Inc. | 48 | $243,694 |
| Novartis | 6 | $146,956 |
| Ipsen Bioscience Inc. | 34 | $100,267 |
| Gilead | 90 | $74,137 |
| Madrigal Pharmaceuticals | 34 | $37,322 |
| Intercept Pharma Europe Ltd. | 8 | $25,326 |
| AbbVie | 57 | $1,011 |
| Johnson & Johnson | 21 | $592 |
| Pfizer | 11 | $332 |
| Boston Scientific | 4 | $304 |
| Intuitive Surgical | 1 | $270 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $232 |
| Novo Nordisk | 2 | $223 |
| Ipsen Biopharmaceuticals, Inc | 5 | $196 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Bristol Myers Squibb | 7 | $118 |
| Alnylam Pharmaceuticals Inc. | 1 | $112 |
| Phathom Pharmaceuticals, Inc. | 4 | $97 |
| Olympus America Inc. | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Sanofi | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Ardelyx, Inc. | 2 | $40 |
| Organon | 2 | $39 |
| Medtronic | 1 | $33 |
| ERBE USA Inc | 1 | $24 |
| Ambu Inc. | 1 | $23 |
| Biocon Biologics Inc | 1 | $23 |
| AstraZeneca | 1 | $22 |
| QOL Medical, LLC | 1 | $19 |
| Celltrion USA Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Digestive Care, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $11 |
How this compares
$946,346 in reported general payments places this provider in the 95th percentile of 81 gastroenterology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Albuquerque
- Sanjeev AroraAlbuquerque$344K
- Christopher ChangAlbuquerque$110K
- Fazia MirAlbuquerque$98K
- Swathi PaletiAlbuquerque$60K
- Howard GogelAlbuquerque$21K
- Stuart WeismanAlbuquerque$19K
- Denis McCarthyAlbuquerque$17K
- Andrei GasicAlbuquerque$9K
- Amal ShineAlbuquerque$7K
- Julie FarrerAlbuquerque$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.